Get the Stockscreener App
109.05
0.08%
0.027
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $109.05, with a volume of 7.86M.
It is up +0.08% in the last 24 hours and down -12.14% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$109.02
Open:
$109.2
24h Volume:
7.86M
Relative Volume:
0.98
Market Cap:
$189.71B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
29.45
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
+2.89%
1M Performance:
-12.14%
6M Performance:
-16.02%
1Y Performance:
-15.48%
1-Day Range:
$107.64
$109.73
1-Week Range:
$105.34
$111.00
52-Week Range:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
109.10 | 189.57B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.77 | 137.99B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
103.06 | 132.28B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
78.19 | 135.87B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
EW
Edwards Lifesciences Corp
|
80.69 | 47.64B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus
Abbott glucose monitor sensor recall classified as most serious by FDA - Seeking Alpha
Abbott recalls glucose sensors after seven deaths linked to faulty readings - Reuters
Do Wall Street Analysts Like Abbott Laboratories Stock? - FinancialContent
FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech
Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat
Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Now 18% Cheaper, Time To Buy - Trefis
Gains Report: Can Abbott Laboratories sustain earnings growthDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Abbott receives FDA warning letter related to FreeStyle Libre CGMs - MassDevice
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered - The Motley Fool
Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story - Yahoo Finance
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch - TechStock²
Abbott CEO Share Purchase Highlights $21b Exact Sciences Deal And Valuation - simplywall.st
Abbott receives FDA warning letter over Freestyle Libre CGMs - MedTech Dive
Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure - Finviz
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT - MarketBeat
Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Lessened by Thrivent Financial for Lutherans - MarketBeat
Abbott Laboratories (ABT): A Bull Case Theory - Insider Monkey
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott (ABT) Sees Increased Bearish Options Activity - GuruFocus
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations - TechStock²
The Best Dividend King to Buy With $150 - AOL.com
ABT: Barclays Adjusts Abbott Laboratories Price Target to $142 | - GuruFocus
Abbott Laboratories (NYSE:ABT) Price Target Cut to $142.00 by Analysts at Barclays - MarketBeat
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors - Seeking Alpha
Barclays Cuts Price Target on Abbott Laboratories to $142 From $169, Maintains Overweight Rating - marketscreener.com
Abbott has 2-year data supporting Tendyne mitral valve replacement - MassDevice
Mawer Investment Management Ltd. Has $168.20 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $142 - 富途牛牛
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT - TechStock²
Assessing Abbott Laboratories (ABT) Valuation After Q4 Nutrition Weakness And Ongoing Device Strength - simplywall.st
Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026 - MSN
Principal Financial Group Inc. Sells 331,362 Shares of Abbott Laboratories $ABT - MarketBeat
Mediolanum International Funds Ltd Acquires 169,026 Shares of Abbott Laboratories $ABT - MarketBeat
Freedom Capital Upgrades Abbott Laboratories (ABT) to Buy - Finviz
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist - Finviz
Abbott Laboratories stock price: ABT ends Friday up 3% — what investors watch next week - TechStock²
Abbott Clears Major Hurdle in $21 Billion Exact Sciences Acquisition - AD HOC NEWS
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Price Target Cut to $119.00 by Analysts at Leerink Partners - MarketBeat
Daiwa Capital Markets Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott Laboratories (NYSE:ABT) Rating Increased to Strong-Buy at Freedom Capital - MarketBeat
Applied Digital, Goldman Sachs, UPS, Abbott, Schlumberger Shake-Up - TipRanks
Private Wealth Partners LLC Purchases 12,025 Shares of Abbott Laboratories $ABT - MarketBeat
Summit Global Investments Lowers Stock Holdings in Abbott Laboratories $ABT - MarketBeat
National Pension Service Has $477.60 Million Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):